Catalyst
Slingshot members are tracking this event:
Gilead (GILD) Initiates Dosing in Phase 2b/3 SELECTION Trial Evaluating Filgotinib in Moderately to Severely Active Ulcerative Colitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dosing Initiation, Phase 2b/3, Selection, Filgotinib, Ulcerative Colitis
